Nutricost Boswellia Extract Review

It’s genuinely standardised — and to a high figure. The boswellia budget aisle is full of sub-$15 bottles that say “Boswellia 500 mg” with no standardisation, which is raw resin powder the trials never tested. Nutricost is the opposite: it states 65% boswellic acids, meaning roughly 780 mg of actual boswellic acids per 1,200 mg serving. That’s a real, high active spec at a value price — the combination of high-strength-standardised and cheap is what earns the bottle its spot. You’re not trading down to resin to save money; you’re getting more standardised active per dollar than almost anything on the list.

Two capsules a day with food gives you 1,200 mg of extract — which lands squarely in the ~1,000 mg/day window Kimmatkar 2003 used for a standardised whole extract. That makes the 180-cap bottle roughly a three-month supply at the full dose. Unlike the lower-strength whole-extract picks that need three caps to reach the window, Nutricost gets you there in two, which is part of why the cost-per-productive-dose is so low. Split it morning and evening if you prefer steadier levels.

Precision on the most potent fraction. Like NOW, Nutricost standardises to total boswellic acids (65%) rather than a stated AKBA percentage — so it trails the AKBA-enriched tier (AprèsFlex in Life Extension, #1) on AKBA enrichment, the specific compound the strongest trial (Sengupta 2008) used at ~30% AKBA. What you keep is high-strength, genuinely-standardised material at the best cost-per-gram on the list. If you want to match the AKBA-enriched evidence exactly, get Life Extension Boswellia (#1); if you want the most standardised boswellia per dollar, this is it.

Yes, for the value tier. Nutricost is a high-volume direct-to-consumer brand that manufactures in a GMP-compliant facility, labels its products non-GMO and gluten-free, and third-party tests its extracts. It isn’t positioned as a clinician-grade marque like Pure Encapsulations or Life Extension, but for a standardised botanical at a value price its QC is reasonable — and a meaningful step up from the unbranded resin filling the rest of the budget shelf. For an adulteration-prone category, a third-party-tested, GMP-made standardised extract is a sensible quality floor.

Because the ranking weights AKBA standardisation most heavily, and Nutricost — like every whole-extract pick — standardises to total boswellic acids rather than a named AKBA fraction. The picks above it either use a named AKBA-enriched extract at its trial dose (Life Extension Boswellia #1), add a complementary co-factor (NOW’s turmeric, #4), or carry a clinician-grade clean label (Pure Encapsulations #4). Nutricost optimises hard for one thing — cost-per-gram of standardised extract — and wins on exactly that. It’s the value champion, not the precision champion.

Anyone whose priority is AKBA precision, a clinician-grade label, or a specific feature rather than cost-per-gram. If you want a named AKBA-enriched extract at its trial dose, get Life Extension Boswellia (#1). If you have a sensitive gut or react to fillers, Pure Encapsulations (#4) is the hypoallergenic pick. If you want boswellia plus curcumin in one bottle, that’s Terry Naturally Curamin (#3). Nutricost is built to deliver the most standardised boswellia per dollar — buy it for that, not for anything else.

1. [1] Kimmatkar 2003 PMID 12622457 — Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee — a randomized double blind placebo controlled trial. Randomised, double-blind, placebo-controlled crossover trial in knee-osteoarthritis patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved function, and increased walking distance versus placebo over 8 weeks. The efficacy and dosing basis (~333 mg three times daily, ~1,000 mg/day) for a standardised extract like Nutricost’s.
2. [2] Sengupta 2008 PMID 18667054 — A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Placebo-controlled trial of 5-Loxin (an AKBA-enriched Boswellia extract, ~30% AKBA) at 100 and 250 mg/day in knee osteoarthritis: significant, dose-related pain and function improvements, with benefits within ~7 days at 250 mg. Defines the AKBA-enriched precision tier Nutricost’s total-boswellic-acid standardisation sits below.